Clinical Trial Update: Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

ClinicalTrials.gov update for OVAX, an autologous hapten-modified vaccine, in relapsed stage III/IV ovarian cancer; the Phase 1/Phase 2 trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• OVAX

Snippet

Sponsor: AVAX Technologies | Conditions: Adenocarcinoma of the Ovary | Phase 1, Phase 2 | Status: UNKNOWN